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Implementation of maternal
blood cell-free DNA testing in
early screening for aneuploidies
Introduction
Aneuploidies are major causes of perina-
tal death and childhood handicap. Con-
sequently, the detection of chromosomal
disorders constitutes the most frequent
indication for invasive prenatal diagno-
sis. However, invasive testing by amnio-
centesis or chorionic villous sampling is
associated with a risk of miscarriage, and
therefore these tests should only be car-
ried out in pregnancies considered to be
at high risk of aneuploidies [1].
Several externally blinded validation
and implementation studies carried out
over the last 9 years have shown that it
is now possible, through analysis of cell-
free (cf)DNA inmaternal blood, to effec-
tively detect a high proportion of fetuses
affected by trisomies 21, 18, and 13at
a much lower false-positive rate (FPR)
than all other existing screening meth-
ods [2]. There is also some evidence that
cfDNAtestingcandetectotherautosomal
trisomies, sexchromosomeaneuploidies,
triploidy, and even sequence the com-
plete fetal genome, which has led some
laboratories to offer screening for fetal
chromosomal aberrations of more than
3–7megabases (Mb)onanychromosome
[2–5].
Since the sensitivity and specificity of
cfDNA testing are not 100%, it should
not be considered a diagnostic test to
replace invasive testing but rather a new
screening test that identifies a high-risk
group requiring further investigation by
invasive testing.
This article is aimed at reviewing tech-
nicalandclinicalconsiderationsof imple-
menting cfDNA testing in routine prac-
tice.
Current practice in screening
for aneuploidies
Methods of screening
In the 1970s, themainmethod of screen-
ing for trisomy 21 was by maternal age
and in the 1980s it was by maternal
serum biochemistry and detailed ultra-
sonographic examination in the second-
trimester. In the 1990s the emphasis
shifted to the first-trimester, when it
was realized that the great majority of
affected fetuses could be identified by
a combination of maternal age, fetal
nuchal translucency (NT) thickness,
maternal serum β-human chorionic go-
nadotropin (β-hCG), and pregnancy-
associated plasma protein A (PAPP-
A). Screening by this combined test
can identify about 90% of fetuses with
trisomy 21 for a FPR of 5% [6]. In
many countries all over the world, like
the UK, there is a national program
of screening for trisomy 21, based on
the combined test and the offer of in-
vasive testing at a certain risk cut-off.
However, in most countries there are
no national guidelines on screening and
individual practitioners offer a variety of
first- and/or second-trimester methods
often driven by market forces and the
rules of supply and demand. Conse-
quently, in some countries, the rate of
invasive testing ranged from 20–40%
before the introduction of cfDNA test-
ing. Since 2012, there has been a rapid
and widespread introduction of cfDNA
testing into clinical practice, first in the
private and then in the public sector,
but similarly, very few countries have
established national policies for offering
cfDNA and those that have done so
have adopted different strategies, from
universal to contingent screening.
Aneuploidies included in screening
Traditionally, screening for aneuploidies
has been focused on trisomy 21. How-
ever, invasive testing in the screen-pos-
itive group often leads to the detection
of many additional clinically significant
aneuploidies. In the case of some ane-
uploidies, such as trisomies 18 and 13,
triploidy and Turner syndrome, their in-
cidence in the screen-positive group for
trisomy 21 is much higher than in the
screen-negative group because they have
a similar pattern in the expression of bio-
physical and biochemical markers [6–9].
Therefore, by using the first-trimester
combined test for the screening of tri-
somy 21, detection of other aneuploidies
was givenatnoextra “cost”, meaningwith
noincrease intheFPR.However, thiscan-
not apply to cfDNA testing because for
every condition we include in the anal-
ysis, we are adding its related FPR. For
example, if we test for trisomy 21 alone,
the FPR is only 0.04%, but if we include
trisomies 18 and 13, the FPR goes up to
0.12% [2] which, although still extremely
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low, would continue to increase with ev-
ery single new condition analyzed.
On the other hand, prenatal detection
of fetal anomalies potentially associated
withgenetic conditionsnecessitates inva-
sive diagnosis, and the use of anymethod
of screening, regardless of its accuracy, is
not an appropriate option in these cases.
Moreover, not only the lack of suf-
ficient scientific evidence is a burden
for including sex chromosome aneu-
ploidies, rare autosomal aneuploidies or
subchromosomal anomalies in routine
cfDNA screening but also the difficulty
in parental counselling when discussing
these conditions, either because of the
wide spectrum of their clinical man-
ifestation or because of inappropriate
understanding of the disease.
For all the reasons above, there are
no current recommendations to include
any other condition in addition to tri-
somies 21, 18, and 13 when requesting
cfDNA testing for screening of aneuploi-
dies, even if it is technically possible [10,
11].
Screening for aneuploidies
by cell-free DNA testing in
maternal blood
Performance of the test in
screening for trisomies 21, 18,
and 13
A recentmeta-analysis in singleton preg-
nancies reported that in the combined to-
talof1963casesof trisomy21and223,932
non-trisomy 21 singleton pregnancies,
the weighted pooled detection rate (DR)
was 99.7% (95% CI, 99.1–99.9%) and the
FPR was 0.04% (95% CI, 0.02–0.07%).
In a total of 563 cases of trisomy 18
and 222,013 unaffected pregnancies,
the pooled weighted DR and FPR were
97.9% (95% CI 94.9–99.1%) and 0.04%
(95% CI 0.03–0.07%) respectively, and
in a total of 119 cases of trisomy 13
and 212,883 unaffected singleton preg-
nancies, the pooled weighted DR and
FPR were 99.0% (95% CI 65.8–100%)
and 0.04% (95% CI 0.02–0.07%) [2].
Similarly, a recent meta-analysis in twin
pregnancies reported that in a combined
total of 56 trisomy 21 and 3,718 non-
trisomy 21 twin pregnancies, the pooled
weighted DR and FPR were 98.2% (95%
CI 83.2–99.8%) and 0.05% (95% CI
0.01–0.26%), respectively. In a total
of 18 cases of trisomy 18 and 3,143
non-trisomy 18 pregnancies, the pooled
weighted DR and FPR were 88.9% (95%
CI 64.8–97.2%) and 0.03% (95% CI
0.00–0.33%) respectively. Although the
number of twin pregnancies with tri-
somy13 (n= 3)was too small for accurate
assessment of the DR, the average FPR
for trisomy 13 of 0.19% (5 out of 2,569)
seems slightly higher than the values
reported for singleton pregnancies [12].
These results show that cfDNA testing
is by far the best available method for
screening of these conditions.
Detection of other aneuploidies
Studies on a smaller number of con-
firmed cases have reported the ability
of cfDNA analysis in maternal blood
to detect sex chromosome aneuploidies,
rare autosomal trisomies, triploidy, mi-
crodeletion and microduplication syn-
dromes, and even monogenic disorders
[5, 13–15]. However, the exact perfor-
mance and clinical utility of the test for
these conditions require further investi-
gation.
Methods for analysis
By parallel sequencing of numerous
cfDNA fragments, millions of nucleotide
sequences can be amplified and se-
quenced. This results in a large amount
of data that bioinformatics have to an-
alyze and compare with the reference
genome. Two main approaches for
analysis have been used in the main
clinical studies assessing performance of
cfDNA testing: massively parallel shot-
gun sequencing (MPSS), by which the
whole genome is analyzed, and targeted
chromosome analysis, either by next-
generation sequencing, custommicroar-
ray or single-nucleotide polymorphisms
(SNP) analysis, which is directed and
limited only to the chromosomes of
interest.
MPSS
Several millions of cfDNA fragments
from maternal plasma are sequenced, of
both maternal and fetal origin. Next, the
origin of each fragment is established
and the number of DNA fragments de-
rived from each of the chromosomes
is quantified. In pregnancies with a
trisomic fetus, the number of molecules
derived from the extra chromosome in
proportion to the rest of the sequenced
molecules (in general, chromosome 3 is
used as a reference) is higher than in
diploid gestations [16, 17]. It requires
a large number of sequences (depth of
sequencing or “coverage”) and a great
biomathematical effort to examine these
numerical changes that, sometimes, are
minute.
By this method, the molecules of all
the chromosomes are examined; thus, it
is potentially able to identify all the ane-
uploidies. However, as chromosome 21
represents only 1–2% of the human
genome, it is necessary to sequence
many millions of molecules from the
whole genome to ensure a minimum
of chromosome 21 counts that allows
differentiation between pregnancies with
trisomy 21 and euploids. This method
has a high performance in the screen-
ing of trisomies 21, 18, and 13 and sex
chromosome aneuploidies, with a low
failure rate (<1%), as not all laborato-




The basic principles are the same as for
MPSS, but by chromosome-selective se-
quencing (CSS) the selective assay is di-
rected against specific regions of chro-
mosomes 21, 18, 13, X, and Y before se-
quencing. CSS evaluates SNPs in other
chromosomes to estimate the fetal frac-
tion [18]. The advantages of this tech-
nique are, in the first place, the theo-
retical reduction in cost, as the number
of regions that need to be sequenced is
substantially lower than when sequenc-
ing the whole genome and, second, the
simultaneous calculationof the fetal frac-
tion in the same assay. The disadvantage
is that the failure rate in providing results
may be somewhat higher (2%) than with
the MPSS, although a recent meta-anal-
ysis did not show significant differences
[2].
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Microarray
Recently a new technique has been
developed that is substituting CSS, in
which, instead of using next-generation
sequencing as a counting method, a cus-
tom microarray is utilized [19]. This
method has shown results comparable
with those obtained by CSS, but more
cost-effectively and with a shorter time
to obtain results [19, 20].
SNPs
Single-nucleotide polymorphisms are
variations of DNA that help distinguish
among different individuals. An SNP
represents a difference in a single nu-
cleotide (a base) within a certain DNA
sequence, which for everything else is
identical among individuals. The SNP-
based method of analyzing cfDNA in
maternal blood is based on the prin-
ciple that the fetus has different SNPs
than the mother. The maternal plasma
is analyzed, which contains a mixture
of maternal and fetal DNA, and the
DNA of the buffy coat, which is only
of maternal origin. Using a conven-
tional polymerase chain reaction (PCR)
variant, the multiplex PCR, more than
13,000 polymorphic loci are quantified
simultaneously on chromosomes 21,
18, 13, X, and Y [15]. As the mother
and fetus have different specific SNP
patterns, these small differences can be
used throughout the genome to esti-
mate whether the fetal distribution in
comparison to the mother’s is consistent
with monosomy, disomy or trisomy. As
a method itself, this technology would
be expected to be the most accurate,
even at lower fetal fractions. However,
this has not been shown in published
studies, with reported performance for
the detection of trisomies 21, 18, and
13 similar to that of MPSS or CSS, but
with a nonsignificantly higher failure
rate (3–5%) [2].
Others
Even before the spread of next-genera-
tion sequencing, many groups were al-
ready working on the development of
a cfDNA test for the screening of ane-
uploidies based on PCR, such as real-
time PCR or digital PCR [21]. There are
already laboratories that offer the test us-
ing this method and, although the vali-
dation studies show results comparable
with those obtained by MPSS, no large-
scale prospective validation study has yet
been published in the general popula-
tion. More recently, a proof-of-principle
study on a method based on highly spe-
cific chromosomal fluorescent labeling
has been published [22].
Limitations of the test
There are twomain limitations of cfDNA
testing in the implementation of this
method of screening for aneuploidies.
First, although the cost of the test is
similar to that of invasive testing and
karyotyping, it is considerably higher
than that of the currently available
screening methods. Second, there is
a rate of failure of the test to provide
results of about 1% [2]. An important
cause of not getting a result from cfDNA
testing is a low fetal fraction, which is
often a consequence of maternal obesity
but also secondary to a small placental
mass [23, 24].
Clinical implementation of cell-
free DNA testing in maternal
blood
Over the last 40 years of screening, we
have learnt that pregnant women are able
to use sophisticated screening informa-
tion to make scientifically and ethically
rational decisions about invasive testing
[25]. In the case of trisomy 21, the
rate of invasive testing increases expo-
nentially with increasing estimated risk
for this aneuploidy and the opposite is
also true [25]. Therefore, although the
main achievement of the introduction of
cfDNA testing as a method of screen-
ing is the substantial reduction in the
invasive testing rate worldwide, a small
proportion of the population at very low
risk for aneuploidies still demands inva-
sive testing for an increasing number of
conditions made possible by molecular
techniques. On the opposite side of the
spectrum, somewomenataveryhighrisk
for aneuploidies choose to avoid having
an invasive test and for them, cfDNAtest-
ing may help to reinforce the suspected
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Several externally blinded validation and
implementation studies in the last 9 years
have shown that it is now possible, through
analysis of cell-free (cf ) DNA in maternal
blood, to effectively detect a high proportion
of fetuses affected by trisomies 21, 18, and
13at a much lower false-positive rate (FPR)
than all other existing screening methods.
This article is aimed at reviewing technical
and clinical considerations for implementing
cfDNA testing in routine practice, including
methods of analysis, performance of the
test, models for clinical implementation, and
interpretation of results.
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aus den letzten neun Jahren haben gezeigt,
dass es inzwischen mithilfe der Analyse
von zellfreier (cf ) DNA im mütterlichen
Blut möglich ist, einen hohen Anteil der
Feten mit Trisomie 21, 18 und 13 mit
einer viel niedrigeren Falsch-Positiv-Rate
(FPR) zu entdecken als bei allen anderen
angewandten Analysemethoden. Ziel dieses
Artikels ist es, die technischen und klinischen
Überlegungen für die Implementierung
von cf-DNA-Tests in die Routinepraxis zu
prüfen, einschließlichder Analysemethoden,
Testdurchführung, Modelle für die klinische
Umsetzung sowie der Interpretation der
Ergebnisse.
Schlüsselwörter
Zellfreie DNA · Nichtinvasive Pränataldia-
gnostik · Trisomien · Pränatales Screening ·
Aneuploidien
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diagnosis and be helpful for pregnancy
care and preparation for the parents.
There are few limitations when of-
fering cfDNA testing because, although
most studies were carried out in high-
risk pregnancies, an increasing number
of studies performing the test in the rou-
tine population have demonstrated that
this test is equally effective in low-risk
pregnancies [2]. Moreover, the test can
be reliably performed at any time during
pregnancy, starting at 10 weeks; thus, the
best approach to implementing screening
for aneuploidies by cfDNA testing in the
routinepopulation is to take thematernal
blood during the first trimester. By do-
ing so, it would be possible to retain the
advantages of first-trimester screening:
first, early reassurance of the majority
of parents that the fetus is unlikely to
be aneuploid and the option for first-
trimester termination of pregnancy for
the few where the fetus is found to be
affected; and second, early diagnosis of
major fetal defects and assessment of the
risk for pregnancy complications [26].
Primary method of screening
There are two possible options: first, to
take the blood at 10 weeks, in which case
the results of the test would be avail-
able at the time of the scheduled first-
trimesterultrasoundexamination, which
is ideally performed at 12 weeks; sec-
ond, to take the blood at 12 weeks, after
the first-trimester examination. Thema-
jor advantage of taking the blood sam-
ple at 10 weeks is that the results of
the test should be available at the time
of the first-trimester scan, which will
then be solely performed to diagnose
major fetal defects and to evaluate the
risk for pregnancy complications. In ad-
dition, it would allow the realization of
a rescue first-trimester combined test in
those cases in which the cfDNA test has
not provided results [27]. However, this
model has the disadvantage of perform-
ing many unnecessary tests for pregnan-
cies that miscarry spontaneously before
the 12th–13thweekor that are diagnosed
as having increased fetal NT or major
defects requiring invasive testing at the
timeof theultrasound [28]. By taking the
blood sample after the first-trimester as-
sessment, these problems would be over-
come, but with the disadvantage of los-
ing the possibility of performing a res-
cue first-trimester combined test in those
cases without a cfDNA result, especially
if the ultrasound was performed in week
13.
Contingent screening based on
the results from another method
of screening
An alternative to universal screening by
cfDNA testing is to offer cfDNA test-
ing contingent on the results of first-line
screening by another method, preferably
the first-trimester combined test. cfDNA
testing could be offered to the high-risk
group as an alternative to invasive test-
ing, aiming to reduce the invasive testing
rate, or to the intermediate-risk group,
aiming to increase theDRof aneuploidies
[29]. The exact risk cut-offs that define
the high- and intermediate-risk groups
depend on the cost of cfDNA testing and
therefore the proportion of the popula-
tion that can be offered this test [30].
Interpretation of results from
cfDNA testing
If cfDNA testing reports a high-risk for
trisomy21, 18or13, it doesnotmean that
the fetus definitely has one of these ane-
uploidies and it is important to confirm
or refute the result by invasive testing. In
contrast, if cfDNA testing reports a low
risk, the parents can be reassured that it
is highly unlikely that the fetus has one
of these aneuploidies. However, these
results should always be interpreted to-
gether with a detailed ultrasound exam-
ination that has excluded increased fetal
NT and major malformations. In those
cases where fetal NT is above 3.5mm or
where there are major fetal defects, ir-
respective of the cfDNA results, parents
shouldbeoffered invasive testingwith ar-
ray analysis, to exclude not only the three
major trisomies but also other chromo-
somal and subchromosomal conditions.
Those caseswhere cfDNAtestingdoes
not provide a result must bemanaged in-
dividually. As explained before, themain
reasonwhythe test fails toprovidea result
is a low fetal fraction and the main de-
terminants for this to occur are maternal
obesity and a low placental mass. In tri-
somies 18 and 13, but not in trisomy 21,
the fetal fraction is lower and the rate of
no-results is therefore higher than in un-
affected pregnancies [31]. Consequently,
those pregnancies in which a result from
cfDNA test is not obtained canbe consid-
ered at high risk for trisomies 18 and 13,
but not for trisomy 21. Themanagement
in these cases will depend essentially on
the reason why the test was performed
in the first place. If there was a pre-
vious screening that had already shown
a low-risk result without fetal defects, it
is preferable to repeat the cfDNA test,
explaining to the parents that there is
>60% chance that a result will be ob-
tained in the second attempt. However,
some pregnant women prefer not to un-
dergo the test again to avoid the anxiety
generated by the inconclusive result of
the first one. In these cases and in those
in which the test fails for the second
time, it is advisable to perform a detailed
ultrasound, looking specifically for fetal
anomalies associated with trisomies 18
and 13 and, if these are present, an inva-
sive test should be recommended [31].
In cases in which previous screening had
already shownahigh risk for these condi-
tions but the detailed ultrasound had not
detected any findings suggestive of fetal
pathology, most patients choose to repeat
the cfDNA test, although some prefer to
undergo an invasive test directly.
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